The city of Dallas, Texas, currently has 266 active clinical trials seeking participants for Cancer research studies.
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Recruiting
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Liver Center of Texas, Dallas, Texas
Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Recruiting
The main objectives of this study are to determine the feasibility and safety of AU-011 treatment of bladder cancer utilizing intratumoral injection with or without intramural injection and with or without laser application.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Non-muscle-invasive Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
Recruiting
The purpose of this study is to better understand how the immune system plays a role in fighting breast cancer and specifically research if the immune system response against breast cancer can be improved with endocrine therapy and cyclin dependent kinase inhibitor therapy in patients with hormone receptor positive breast cancer. This will be studied by collecting tumor tissue and blood samples before and after 2 weeks of study treatment with commonly used endocrine therapy and cyclin dependent... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Parkland Hospital, Dallas, Texas +1 locations
Conditions: Breast Cancer
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Recruiting
ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 5,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the identification of clinically actionable cancer-specific biomarkers to guide therapeutic decisions. Four types of solid tumor cancers will be profiled including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), colorectal cancer (CRC) and pancreatic c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Southwest Family Medicine Associates, Dallas, Texas
Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Pancreatic Cancer & Surgical Resection
Recruiting
Primary Objective(s) To collect clinical data related to the treatment outcomes of Pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical intervention. Secondary Objective(s) To collect data on adverse events and complications related to IRE treatment. The AHPBA (Americas Hepato-Pancreato-Biliary Association) will be responsible for data collection and will periodically audit the data for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Liver Institute of Methodist Dallas Medical Center, Dallas, Texas
Conditions: Pancreas Cancer
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Recruiting
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Mary Crowley Center, Dallas, Texas
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Renal Cell Cancer Metastatic, Renal Cell Carcinoma, Prostate Cancer
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Recruiting
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Advanced Cancer, Metastatic Cancer
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
Recruiting
The investigators' preclinical data have demonstrated the feasibility of fluorescence-guided tumor resection by Cancer Vision Goggles (CVG) with LS301 in animal models. In this study, the investigators will conduct intraoperative imaging procedures that have minimal interference with ongoing surgery. The underlying hypothesis is that the accurate detection of all cancer cells highlighted by LS301 during surgery will reduce the number of breast cancer patients with margin positivity to less than... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Breast Cancer, Cancer of the Breast
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Recruiting
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: NEXT Oncology, Dallas, Dallas, Texas
Conditions: Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
Recruiting
This study will assess the safety and efficacy of increasing doses of narazaciclib (ON 123300) in combination with the standard daily dose (2.5mg) of letrozole in patients with Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer and other Gynecologic Malignancies.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas
Conditions: Endometrioid Endometrial Cancer
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy
Recruiting
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Prostate Cancer
GCC19CART for Patients With Metastatic Colorectal Cancer
Recruiting
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2023
Locations: Baylor Scott & White Research Institute, Dallas, Texas
Conditions: Colorectal Cancer